Nebupent Generic Name & Formulations
Pentamidine isethionate 300mg/vial; lyophilized pwd for inhalation after reconstitution. To be used with the Respirgard II nebulizer.
For prevention of Pneumocystis jiroveci pneumonia (PJP) in high-risk, HIV-infected patients defined by one or both of the following criteria: 1) a history of one or more episodes of PJP; 2) a peripheral CD4+ lymphocyte count ≤200/mm3.
Nebupent Dosage and Administration
>16yrs: 300mg once every 4 weeks administered via the Respirgard II nebulizer. Dose should be delivered until nebulizer chamber is empty (approx. 30–45 minutes).
≤16yrs: not recommended.
Nebupent Boxed Warnings
Exclude the presence of PJP before starting prophylaxis therapy. History of smoking or asthma. May induce bronchospasm/cough; administer inhaled bronchodilator prior to giving NebuPent dose; do not use Respirgard II nebulizer to administer a bronchodilator. Pregnancy (Cat. C). Nursing mothers: not recommended.
Do not mix with other drugs. Additive effects with concomitant other nephrotoxic drugs (eg, aminoglycosides, amphotericin B, cisplatin, foscarnet, vancomycin); monitor closely or avoid if possible.
Nebupent Adverse Reactions
Night sweats, GI upset, anemia, bronchitis, herpes, herpes zoster, flu, oral Candida, pharyngitis, sinusitis, upper respiratory tract infections, headache, chest pain, cough, wheezing, bad taste; monitor closely for serious adverse reactions: hypotension, hypoglycemia, hyperglycemia, hypocalcemia, thrombocytopenia, leukopenia, hepatic/renal dysfunction, ventricular tachycardia, pancreatitis (discontinue if occurs), Stevens-Johnson syndrome, hyperkalemia, abnormal ST segment; rare: extrapulmonary pneumocystosis.
Nebupent Clinical Trials
Nebupent Patient Counseling